Phenotype Guided Vasoactive Medication During Kidney Transplantation

StatusEnrolling by Invitation
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrolling by invitation only
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 5 of 8 entries
    • Collaborators expanded, about 3 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this clinical trial is to learn if vasopressin improves the body's response to intravenous fluids during kidney transplantation in patients who have relaxed blood vessels. Researchers will compare the results of vasopressin to those who received calcium chloride.
Trial Details
NCT Number NCT07633600
Lead Sponsor Jennifer Cutler
Collaborators: Cedars-Sinai Medical Center
Conditions
(from sponsor)		 Kidney Transplant, Fluid Management
Enrollment 255 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov